Differences in Management Between Dermatologists and Oncologists for Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors

Sarah Oliel; Rachel Bierbrier; Kathleen D'Aguanno; Khashayar Esfahani; Kevin Pehr

doi:10.1177/12034754231217248

Differences in Management Between Dermatologists and Oncologists for Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors

J Cutan Med Surg. 2024 Jan-Feb;28(1):79-81. doi: 10.1177/12034754231217248. Epub 2023 Dec 29.

Authors

Sarah Oliel¹, Rachel Bierbrier², Kathleen D'Aguanno³, Khashayar Esfahani^{4

5

6}, Kevin Pehr^{1

5

7}

Affiliations

¹ Faculty of Medicine, McGill University, Montréal, QC, Canada.
² Division of Dermatology, McGill University, Montréal, QC, Canada.
³ Division of Dermatology, Université de Sherbrooke, Sherbrooke, QC, Canada.
⁴ St. Mary's Hospital, McGill University, Montréal, QC, Canada.
⁵ Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montréal, QC, Canada.
⁶ Division of Medical Oncology, Sir Mortimer B. Davis Jewish General Hospital, Montréal, QC, Canada.
⁷ Lady Davis Institute for Medical Research, Montréal, QC, Canada.

PMID: 38156654
DOI: 10.1177/12034754231217248

No abstract available

Keywords: acneiform eruption; cutaneous adverse event; epidermal growth factor receptor inhibitor; papulopustular eruption; tyrosine kinase inhibitor.

Publication types

Letter

MeSH terms

Acneiform Eruptions* / chemically induced
Acneiform Eruptions* / drug therapy
Dermatologists
ErbB Receptors
Humans
Oncologists*

Substances

ErbB Receptors